Nasdaq:US$13.88 (+0.60) | HKEX:HK$22.35 (+0.90) | AIM:£2.36 (+0.16)
2000
FOUNDED
HCM
NASDAQ &
LONDON AIM
13
HKEX
13
IN-HOUSE DISCOVERED
CLINICAL STAGE CANCER
DRUG CANDIDATES
3
APPROVED & MARKETED
PRODUCTS IN CHINA
1
IN-LICENSED PRODUCT
LAUNCHED IN CHINA
HAINAN PILOT ZONE
~40
CLINICAL TRIALS WORLDWIDE
INCLUDING 13 REGISTRATION STUDIES
4,900
PERSONNEL ACROSS
THE GROUP

OUR SCIENCE

Our core research and development philosophy is to take a holistic approach and treat cancer and immunological diseases through multiple modalities and mechanisms. We have taken a science-focused approach to develop highly selective, potent and well-tolerated cancer therapies that are deliberately engineered to improve drug exposure and reduce off-target toxicities.

R&D Philosophy Pipeline Products

Events, Circulars And Forms


2022 Half-Year Financial Results 2022-08-01 - 2022-08-01
Jefferies Healthcare Conference 2022-06-10
Jefferies Asia Forum 2022-09-07 - 2022-09-09